Cargando…
Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients—a randomized clinical trial
BACKGROUND: Pseudomonas aeruginosa infections are a serious threat in intensive care units (ICUs). The aim of this confirmatory, randomized, multicenter, placebo-controlled, double-blind, phase 2/3 study was to assess the efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginos...
Autores principales: | Adlbrecht, Christopher, Wurm, Raphael, Depuydt, Pieter, Spapen, Herbert, Lorente, Jose A., Staudinger, Thomas, Creteur, Jacques, Zauner, Christian, Meier-Hellmann, Andreas, Eller, Philipp, Laenen, Margot Vander, Molnár, Zsolt, Várkonyi, István, Schaaf, Bernhard, Héjja, Mária, Šrámek, Vladimír, Schneider, Hauke, Kanesa-thasan, Niranjan, Eder-Lingelbach, Susanne, Klingler, Anton, Dubischar, Katrin, Wressnigg, Nina, Rello, Jordi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057595/ https://www.ncbi.nlm.nih.gov/pubmed/32131866 http://dx.doi.org/10.1186/s13054-020-2792-z |
Ejemplares similares
-
Molecular and epidemiologic analysis of dengue virus isolates from Somalia.
por: Kanesa-thasan, N, et al.
Publicado: (1998) -
Safety and Immunogenicity of MF59-Adjuvanted Cell Culture–Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly
por: Frey, Sharon E, et al.
Publicado: (2019) -
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
por: Schneider, Martina, et al.
Publicado: (2023) -
EFFECTS OF HOMOLOGOUS AND HETEROLOGOUS BOOSTER VACCINATIONS OF THE INACTIVATED DUAL-ADJUVANTED VACCINE VLA2001 AGAINST COVID-19 INCLUDING VARIANTS OF CONCERN: A PHASE 3 RANDOMIZED CLINICAL TRIAL
por: Wressnigg, N., et al.
Publicado: (2023) -
Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial
por: Lazarus, Rajeka, et al.
Publicado: (2022)